NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

https://seekingalpha.com/article/4666789-merck-and-co-inc-mrk-q4-2023-earnings-call-transcript

Chris, thanks for the question. Obviously, first, I just want to reinforce the pride I have in what Dean and the team have been able to do and the meaningful progress we are making both in our internal pipeline and what we have been able to do through the business development, which is I think in some ways, in a weird way, underlying your question. But as we sit here today, while I feel very good about the progress we have made in the growing portfolio, the diverse and deep portfolio we have in our pipeline, we do continue to believe we need more, and we will continue to prioritize business development. And I would say that our views of deals like Prometheus, like Acceleron are still the size of deals we are very interested in, if we can find great assets. So, clearly that’s an area of focus. But also continuing to do smaller deals as well, like what you saw with Harpoon. So, it’s going to be a range of deals. But I think as you look in that zero to kind of $15 billion, $1 billion to $15 billion, it continues to be where we will look for. And then obviously, we have also, I think shown that not only are we very open to doing an acquisition, but we see collaboration as an important tool as well, very similar to what we did with Daiichi Sankyo. So, we are going to be looking at the full suite and including deals that fit those categories.